Novo Nordisk A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novo Nordisk A/S
The path of spin-offs from loss-making biotech companies with weak investment propositions seems clouded with examples that often resulted in an appointment with the liquidator.
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.
- Large Molecule
- Other Names / Subsidiaries
- Corvidia Therapeutics
- Neose Technologies, Inc.
- Novo Holdings A/S
- Novo Nordisk Pharmaceuticals, Inc.
- Pharmaero Aps
- Xellia Pharmaceuticals ApS
- Ziylo Ltd